famotidine has been researched along with Kidney Neoplasms in 9 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Kidney Neoplasms: Tumors or cancers of the KIDNEY.
| Excerpt | Relevance | Reference |
|---|---|---|
| " It has been previously shown that the patients with metastatic melanoma or kidney cancer may be treated safely with pulse IL-2 daily for 5 days preceded by intravenous famotidine." | 7.77 | Pulse interleukin-2 with famotidine induces CD56+ lymphocytes in the peripheral blood of patients with metastatic melanoma or kidney cancer. ( Gagnon, GA; Quan, FM; Quan, WD; Walker, PR, 2011) |
| "Famotidine may increase IL-2 internalization by the IL-2 receptor on T-lymphocytes." | 5.35 | Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer. ( King, LA; Quan, FM; Quan, WD; Walker, PR, 2008) |
| "Two (2) patients with kidney cancer have been converted to complete responders with resection of residual disease, remaining without relapse at 5+ and 20+ months." | 5.33 | Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2. ( Elsamaloty, HM; Ghai, V; Liles, DK; Quan, FM; Quan, WD; Ramirez, M; Vinogradov, M; Walker, PR, 2006) |
| " It has been previously shown that the patients with metastatic melanoma or kidney cancer may be treated safely with pulse IL-2 daily for 5 days preceded by intravenous famotidine." | 3.77 | Pulse interleukin-2 with famotidine induces CD56+ lymphocytes in the peripheral blood of patients with metastatic melanoma or kidney cancer. ( Gagnon, GA; Quan, FM; Quan, WD; Walker, PR, 2011) |
| "Famotidine may enhance the LAK activity by increasing IL-2 internalization by the IL-2 receptor on lymphocytes." | 1.40 | Activity of outpatient intravenous interleukin-2 and famotidine in metastatic clear cell kidney cancer. ( Quan, FM; Quan, WD, 2014) |
| "Famotidine may increase IL-2 internalization by the IL-2 receptor on T-lymphocytes." | 1.35 | Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer. ( King, LA; Quan, FM; Quan, WD; Walker, PR, 2008) |
| "Famotidine may enhance LAK cytolytic ability." | 1.33 | High-dose continuous infusion plus pulse interleukin-2 and famotidine in metastatic kidney cancer. ( Khan, N; Quan, F; Quan, W; Ramirez, M; Taylor, C; Vinogradov, M, 2005) |
| "Two (2) patients with kidney cancer have been converted to complete responders with resection of residual disease, remaining without relapse at 5+ and 20+ months." | 1.33 | Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2. ( Elsamaloty, HM; Ghai, V; Liles, DK; Quan, FM; Quan, WD; Ramirez, M; Vinogradov, M; Walker, PR, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (77.78) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Quan, WD | 7 |
| Quan, FM | 6 |
| Gagnon, GA | 1 |
| Walker, PR | 5 |
| Quan, W | 2 |
| Ramirez, M | 3 |
| Taylor, C | 2 |
| Quan, F | 2 |
| Vinogradov, M | 4 |
| Walker, P | 1 |
| Khan, N | 2 |
| Khuder, SA | 1 |
| Elsamaloty, HM | 1 |
| Ghai, V | 1 |
| Liles, DK | 2 |
| King, LA | 1 |
1 review available for famotidine and Kidney Neoplasms
| Article | Year |
|---|---|
Continuous infusion interleukin-2 and antihistamines in metastatic kidney cancer.
Topics: Adjuvants, Immunologic; Antineoplastic Agents; Cimetidine; Famotidine; Histamine; Histamine H1 Antag | 2005 |
3 trials available for famotidine and Kidney Neoplasms
| Article | Year |
|---|---|
High-dose intensity pulse interleukin-2 with famotidine in metastatic kidney cancer.
Topics: Aged; Cytokine-Induced Killer Cells; Disease Progression; Drug Administration Schedule; Drug Interac | 2009 |
Administration of high-dose continuous infusion interleukin-2 to patients age 70 or over.
Topics: Adenosine; Aged; Aged, 80 and over; Aging; Capillary Leak Syndrome; Famotidine; Hemodynamics; Humans | 2005 |
Continuous infusion interleukin-2 and famotidine in metastatic kidney cancer.
Topics: Adult; Aged; Drug Administration Schedule; Drug Synergism; Famotidine; Female; Humans; Immunotherapy | 2006 |
5 other studies available for famotidine and Kidney Neoplasms
| Article | Year |
|---|---|
Activity of outpatient intravenous interleukin-2 and famotidine in metastatic clear cell kidney cancer.
Topics: Administration, Intravenous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2014 |
Pulse interleukin-2 with famotidine induces CD56+ lymphocytes in the peripheral blood of patients with metastatic melanoma or kidney cancer.
Topics: CD56 Antigen; Famotidine; Humans; Infusions, Intravenous; Interleukin-2; Kidney Neoplasms; Killer Ce | 2011 |
High-dose continuous infusion plus pulse interleukin-2 and famotidine in metastatic kidney cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Famotidine; Female; Histamine H2 Anta | 2005 |
Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2.
Topics: Aged; Drug Administration Schedule; Drug Synergism; Famotidine; Female; Humans; Immunotherapy; Infus | 2006 |
Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Renal Cell; Cycloph | 2008 |